Category: 1774893-22-9

On March 19, 2020, Akahoshi, Issei; Sumikawa, Yoshitake; Furuta, Sadayoshi; Fukushima, Keiichiro; Imazu, Takuya; Kotaka, Ryota published a patent.Quality Control of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid The title of the patent was Preparation of novel heteroaromatic amide derivatives and medicines containing them. And the patent contained the following:

The present invention provides novel heteroaromatic amide derivatives I [X1-X2 = N-C or C-N; Y1, Y2, Y3 and Y4 = independently single bond, -CH2-, -CR4aH-, CR4bH-, NR4c-, -O-, etc.; Z1 = single bond, -O-, -S-, etc.; ring A = a 3-7-membered monocyclic aromatic ring or an 8-12-membered bicyclic aromatic ring; R1a and R1b = H, halogen, alkyl, etc.; R2 = H, halogen, OH, etc.; R3a, R3b and R3c = independently H, halogen, CN, (un)substituted C1-6 alkyl, (un)substituted C1-6 haloalkyl, etc.; R4a, R4b, and R4c = independently (un)substituted C1-6 haloalkyl or C1-6 haloalkoxy, etc.; R5a = H, alkyl, etc.; R5b = H, alkyl, etc.; R5c = H, alkyl, etc.; R5a and R5b can join together to form -CH2O- or the like; R6a and R6b = independently H, halogen, alkyl, etc.; n = 1 or 2] and medicines containing them. For example, compound II (preparation given) was coupled with compound III to provide compound IV. The invention compounds selectively inhibit Nav1.7 rather than Nav1.5, and they are highly effective for various diseases associated with Nav1.7 such as pain. The experimental process involved the reaction of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid(cas: 1774893-22-9).Quality Control of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid

The Article related to heteroaromatic amide derivative preparation nav inhibitor pain treatment, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Quality Control of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On September 16, 2021, Akaboshi, Kazumasa; Sumikawa, Eiken; Furuta, Sadayoshi; Imazu, Takuya; Fukushima, Keiichiro; Furutaka, Ryota published a patent.Name: 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid The title of the patent was Preparation of heteroaromatic amide derivative for inhibiting Nav1.7. And the patent contained the following:

The present invention relates to a compound I [X-Y = N-C or C-N; Y1-Y4 = independently single bond, -CH2-, -CH2CH2-, etc.; Z1 = single bond, -O-, -S-, etc.; ring A = monocyclic aromatic ring or bicyclic aromatic ring; R1a, R1b = independently H, halo, hydroxy, etc.; R2 = H, halo, hydroxy, etc.; R3a, R3b, R3c = independently H, halo, cyano, etc.; combination of R5a, R5b, R5c, R6a, R6b and n is selected from (1), (2), (3), etc.; (1) R5b and R5c combine to form a single bond, -CH2-, -OCH2-, etc., R5a is H, alkyl, haloalkyl, etc., R6a and R6b each is H, halo, hydroxy, etc., and n is 1 or 2 (2) R5a and R6a combine to form -CH2-, -CH2CH2-, -CH2CH2O-, etc., R5b is H, alkyl or haloalkyl, R5c and R6b each is H, halo, hydroxy, etc. (or R5c and R6b may combine to form -(CH2)p-, -O(CH2)p-, -(CH2)pO-, etc. (p = 0-3)), and n is 1 (3) R5a is H, alkyl, haloalkyl, etc., R5b is H or alkyl, R5c is H, alkyl or halo, R6a and R6b each is H, halo, alkyl, etc. (or R6a and R6b, together with the carbon atom to which they are attached, may combine to form a monocyclic ring) and n is 1 or 2; or a salt thereof]. For example, compound II was prepared via cyclization of 5-(trifluoromethyl)pyridin-2-amine with Et bromopyruvate, hydrogenation, hydrolysis and HATU-mediated amidation with 6-fluorochroman-3-amine·HCl. Compound I shows selective inhibition of potential-dependent sodium channel Nav1.7 over Nav1.5, and is useful for the treatment of pain and various Nav1.7-related disease including pruritus and an autonomic nerve-related disease. The experimental process involved the reaction of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid(cas: 1774893-22-9).Name: 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid

The Article related to heteroaromatic amide preparation voltage gated sodium channel blocker, analgesic heteroaromatic amide, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Name: 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On March 19, 2020, Akahoshi, Issei; Sumikawa, Yoshitake; Furuta, Sadayoshi; Fukushima, Keiichiro; Imazu, Takuya; Kotaka, Ryota published a patent.Recommanded Product: 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid The title of the patent was Preparation of heteroaromatic amide derivative for inhibiting Nav1.7. And the patent contained the following:

The present invention relates to a compound I [X-Y = N-C or C-N; Y1-Y4 = independently single bond, -CH2-, -CH2CH2-, etc.; Z1 = single bond, -O-, -S-, etc.; ring A = monocyclic aromatic ring or bicyclic aromatic ring; R1a, R1b = independently H, halo, hydroxy, etc.; R2 = H, halo, hydroxy, etc.; R3a, R3b, R3c = independently H, halo, cyano, etc.; combination of R5a, R5b, R5c, R6a, R6b and n is selected from (1), (2), (3), etc.; (1) R5b and R5c combine to form a single bond, -CH2-, -OCH2-, etc., R5a is H, alkyl, haloalkyl, etc., R6a and R6b each is H, halo, hydroxy, etc., and n is 1 or 2 (2) R5a and R6a combine to form -CH2-, -CH2CH2-, -CH2CH2O-, etc., R5b is H, alkyl or haloalkyl, R5c and R6b each is H, halo, hydroxy, etc. (or R5c and R6b may combine to form -(CH2)p-, -O(CH2)p-, -(CH2)pO-, etc. (p = 0-3)), and n is 1 (3) R5a is H, alkyl, haloalkyl, etc., R5b is H or alkyl, R5c is H, alkyl or halo, R6a and R6b each is H, halo, alkyl, etc. (or R6a and R6b, together with the carbon atom to which they are attached, may combine to form a monocyclic ring) and n is 1 or 2; or a salt thereof]. For example, compound II was prepared via cyclization of 5-(trifluoromethyl)pyridin-2-amine with Et bromopyruvate, hydrogenation, hydrolysis and HATU-mediated amidation with 6-fluorochroman-3-amine·HCl. Compound I shows selective inhibition of Nav1.7 over Nav1.5, and is useful for the treatment of pain and various Nav1.7-related disease. The experimental process involved the reaction of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid(cas: 1774893-22-9).Recommanded Product: 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid

The Article related to heteroaromatic amide preparation voltage gated sodium channel blocker, analgesic heteroaromatic amide, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Recommanded Product: 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On June 24, 2021, Machacek, Michelle; Altman, Michael D.; Huang, Chunhui; Reutershan, Michael H.; Sloman, David L.; Siliphaivanh, Phieng; Schneider, Sebastian E.; Yeung, Charles S.; Witter, David J.; Gibeau, Craig R.; Ye, Yingchun published a patent.Safety of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid The title of the patent was Protein-arginine N-methyltransferase PRMT5 inhibitors for therapy. And the patent contained the following:

The present invention provides compounds and pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. These compounds can treat cancer, sickle cell, and hereditary persistence of fetal Hb mutations. The experimental process involved the reaction of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid(cas: 1774893-22-9).Safety of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid

The Article related to methyltransferase prmt5 inhibitor pharmaceutical, Pharmacology: Other (All Agents and Effects Not Otherwise Assignable) and other aspects.Safety of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On January 20, 2022, Venkatraman, Shankar; Katz, Jason; Roush, William R.; Seidel, Hans Martin published a patent.Category: imidazoles-derivatives The title of the patent was Preparation of indoles, imidazopyridines, pyrazolopyrimidines and related heterocycles useful alone or in compositions in treatment of diseases associated with STING activity. And the patent contained the following:

The invention relates to preparation of indoles, imidazopyridines, pyrazolopyrimidines and related heterocycles(I) or a pharmaceutically acceptable salt, hydrate, cocrystal, or drug combination that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Compounds I wherein X1 and X2 each independently is O, S, N, etc.; Z and Y1-Y3 each independently is heteroaryl; ring B is bicyclic or polycyclic C5-15 cycloalkyl or C5-15 cycloalkenyl, etc.; etc., are claimed. The example compound II was prepared via 4-steps synthesis using 5-bromo-1H-indole as starting material (procedure given). Compounds I were evaluated for their biol. activity (data given). Compounds I are useful, e.g., for treating a diseases in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathol. and/or symptoms and/or progression of the disease (e.g., cancer) in a subject (e.g., a human). The experimental process involved the reaction of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid(cas: 1774893-22-9).Category: imidazoles-derivatives

The Article related to pyrazolopyrimidine preparation sting activation inhibitor cancer disease treatment, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Category: imidazoles-derivatives

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On May 31, 2019, Vadivelu, Saravanan; Rajagopal, Sridharan; Burri, Raghunadha Reddy; Garapaty, Shivani; Sivanandhan, Dhanalakshmi; Thakur, Manish Kumar; Natarajan, Tamizharasan; Swamy, Indu N.; Nagaraju, Nagendra; Kanagaraj, Subramaniam; Mohd, Zainuddin; Sarkar, Sayantani; Samanta, Swapan Kumar; Hariprakash published a patent.Computed Properties of 1774893-22-9 The title of the patent was Preparation of heterocyclic compounds as PRMT5 inhibitors. And the patent contained the following:

The invention relates to compounds of formula I and their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof as PRMT5 inhibitors; their preparation and use in the treatment of and/or prevention of various diseases, including cancer and infectious diseases. Compounds of formula I wherein A is substituted isoquinolinyl, dihydroindenylamino; dashed bond is optional single or double bond; n = 0-1; m = 0-2; p = 1-2; q = 1-3; R1 – R6 are independently H, halo, OH, etc.; R7 is H, C1-6 (un)substituted alkyl, (un)substituted aryl, etc.; R8 is absent, H, halo, C1-6 alkyl, etc.; R10 is H, halo, OH, CN, etc.; X, Y and Z are independently NH and derivatives, O, S, etc.; W and B are independently N and C; and their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof, are claimed. Example compound II was prepared by amidation of 6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxylic acid with 1-amino-3-(3,4-dihydroisoquinolin-2(1H)-yl)propan-2-ol. The invention compounds were evaluated for their PRMT5 inhibitory activity. From the assay, it was determined that compound II exhibited IC50 value ranged from 0.01-1 渭M. The experimental process involved the reaction of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid(cas: 1774893-22-9).Computed Properties of 1774893-22-9

The Article related to heterocycle preparation prmt5 inhibitor treatment cancer infection, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Computed Properties of 1774893-22-9

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On May 31, 2019, Vadivelu, Saravanan; Rajagopal, Sridharan; Burri, Raghunadha Reddy; Garapaty, Shivani; Sivanandhan, Dhanalakshmi; Thakur, Manish Kumar; Natarajan, Tamizharasan; Swamy, Indu N.; Nagaraju, Nagendra; Kanagaraj, Subramaniam; Mohd, Zainuddin; Sarkar, Sayantani; Samanta, Swapan Kumar; Hariprakash published a patent.Synthetic Route of 1774893-22-9 The title of the patent was Preparation of heterocyclic compounds as PRMT5 inhibitors. And the patent contained the following:

The invention relates to compounds of formula I and their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof as PRMT5 inhibitors; their preparation and use in the treatment of and/or prevention of various diseases, including cancer and infectious diseases. Compounds of formula I wherein A is substituted isoquinolinyl, dihydroindenylamino; dashed bond is optional single or double bond; n = 0-1; m = 0-2; p = 1-2; q = 1-3; R1 – R6 are independently H, halo, OH, etc.; R7 is H, C1-6 (un)substituted alkyl, (un)substituted aryl, etc.; R8 is absent, H, halo, C1-6 alkyl, etc.; R10 is H, halo, OH, CN, etc.; X, Y and Z are independently NH and derivatives, O, S, etc.; W and B are independently N and C; and their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof, are claimed. Example compound II was prepared by amidation of 6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxylic acid with 1-amino-3-(3,4-dihydroisoquinolin-2(1H)-yl)propan-2-ol. The invention compounds were evaluated for their PRMT5 inhibitory activity. From the assay, it was determined that compound II exhibited IC50 value ranged from 0.01-1 渭M. The experimental process involved the reaction of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid(cas: 1774893-22-9).Synthetic Route of 1774893-22-9

The Article related to heterocycle preparation prmt5 inhibitor treatment cancer infection, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Synthetic Route of 1774893-22-9

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem